<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03120234</url>
  </required_header>
  <id_info>
    <org_study_id>MK/2950/MD/13121</org_study_id>
    <nct_id>NCT03120234</nct_id>
  </id_info>
  <brief_title>Comparison of Opioid Based and Opioid Free Anaesthesia in Transsphenoidal Surgery</brief_title>
  <official_title>Comparison of Opioid Based and Opioid Free Anaesthesia in Transsphenoidal Surgery for Haemodynamic Stability and Recovery Characteristics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been planned to compare the effect of opioid free anaesthesia using&#xD;
      dexmedetomidine and ketamine with opioid based anaesthesia using fentanyl in maintaining the&#xD;
      intraoperative hemodynamic stability and recovery characteristics in patients undergoing&#xD;
      Transsphenoidal surgery of pituitary tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opioid Free Anesthesia (OFA) is a technique where no intraoperative opioid is administered&#xD;
      during the anesthetic management. Opioid free anesthesia is usually achieved through&#xD;
      sympatholysis, analgesia, and anesthesia with dexmedetomidine and analgesia with low dose&#xD;
      ketamine. In addition paracetamol and other non-steroidal anti inflammatory drugs (NSAIDS)&#xD;
      may be used as adjuncts to the multi-modal pain regimen.&#xD;
&#xD;
      Dexmedetomidine, a highly selective agonist of the alpha2 adrenergic receptor, has many&#xD;
      clinical benefits, such as sedation, analgesia, preventing unwanted stress responses and low&#xD;
      risk of respiratory depression. Because of concern that opioids might cause perioperative&#xD;
      respiratory depression, substitution with dexmedetomidine will be helpful with its analgesic&#xD;
      and sympatholytic properties. Dexmedetomidine has shown to reduce minimum alveolar&#xD;
      concentration (MAC) of inhalational anesthetics and the requirement of perioperative opioid&#xD;
      by 30-50%. In neurosurgical patients, dexmedetomidine is helpful in maintaining intracranial&#xD;
      pressure (ICP) and intraoperative hemodynamic stability, especially during intubation and&#xD;
      extubation. It can allow for faster awakening and thus an earlier neurological examination by&#xD;
      decreasing necessary volatile agent and opioid doses.&#xD;
&#xD;
      Ketamine, an N-methyl-d-aspartate(NMDA) antagonist, blunts central pain sensitization at&#xD;
      sub-anesthetic doses (0.5 mg/kg or less) and has been studied extensively as an adjunct for&#xD;
      perioperative analgesia. Sub-anesthetic ketamine improves pain scores and reduces&#xD;
      perioperative opioid consumption in a broad range of surgical procedures.Recent literature&#xD;
      has suggested that adjuvant ketamine administration in mechanically ventilated patients has&#xD;
      no cerebrovascular effects.&#xD;
&#xD;
      The present study has been planned to compare the effect of opioid free anesthesia using&#xD;
      dexmedetomidine and ketamine with opioid based anesthesia using fentanyl in maintaining the&#xD;
      intraoperative hemodynamic stability and recovery characteristics in patients undergoing TSS&#xD;
      of pituitary tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the emerence and extubation times in both groups</measure>
    <time_frame>15minutes</time_frame>
    <description>it is measured by noting the time for emergence and extubation after stopping inhalational anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to measure the level of emergence in both the groups</measure>
    <time_frame>15min</time_frame>
    <description>using Riker sedation-agitation score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to measure the level of cognition in both the groups</measure>
    <time_frame>15min</time_frame>
    <description>using Short orientation memory concentration test (SOMC test)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of intraoperative hemodynamic stability in both the groups</measure>
    <time_frame>intra operative period</time_frame>
    <description>this will be done by monitoring intraoperative hemodynamics and noting down no of events of hypotension and hypertension and noting down the rescue drug requirements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain assessment by using numeric rating scale</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparing postoperative analgesic dose requirement in both the groups</measure>
    <time_frame>24hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Opioid Free Anaesthesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine and ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Dexmedetomidine and ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>Dexmedetomidine and ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>fentanyl and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>o.9% normal saline will be used instead of ketamine</description>
    <arm_group_label>fentanyl and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients suffering significant pituitary adenocarcinomas posted for transsphenoidal&#xD;
             resection of tumor&#xD;
&#xD;
          -  age group between 18 to 65 yr&#xD;
&#xD;
          -  Both males and females&#xD;
&#xD;
          -  ASA physical status 1 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pts taking opioid for chronic pain&#xD;
&#xD;
          -  Pregnant or nursing woman&#xD;
&#xD;
          -  Preoperative GCS &lt;15&#xD;
&#xD;
          -  HR&lt;50/min&#xD;
&#xD;
          -  Patients with allergies to study medication&#xD;
&#xD;
          -  Patients with psychiatric disorder&#xD;
&#xD;
          -  Patients with unstable cardiorespiratory disorder&#xD;
&#xD;
          -  Patients with hepatic and renal insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AYYAWAR HAREESH, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Post Graduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Post graduation institute of medical education and research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ayyawar Hareesh</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

